Get startedLog in
    Picture of IDEAYA Biosciences logo

    IDYA — IDEAYA Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapNeutral
    All News

    IDEAYA Biosciences Q1 net loss widens, misses expectations on higher R&D spends

    Picture of IDEAYA Biosciences logoIDEAYA Biosciences
    05/05/2026 11:17
    Overview

US precision oncology firm's Q1 net loss widened, missing analyst expectations

Collaboration revenue for Q1 declined from prior quarter

Company reported positive topline results from Phase 2/3 darovasertib trial in uveal melanoma

Outlook

IDEAYA targets completion of NDA filing for darovasertib in H2 2026

Company expects multiple clinical data updates and trial initiations in H2 2026

IDEAYA maintains cash runway guidance into 2030

Result Drivers

R&D EXPENSES - Higher research and development costs driven by increased clinical trial and personnel expenses to support pipeline programs

G&A EXPENSES - General and administrative costs rose due to higher personnel expenses and commercial preparation for darovasertib

PIPELINE INVESTMENT - Ongoing investment in clinical programs and pipeline expansion contributed to higher operating expenses

Company press release: ID:nPn4ftbGVa

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q1 Collaboration Revenue$6.56 mln
    Q1 EPSMiss-$1.11-$0.99 (16 Analysts)
    Q1 Net IncomeMiss-$98.54 mln-$87.02 mln (13 Analysts)
    Q1 Profit From OperationsMiss-$108.54 mln-$97.63 mln (14 Analysts)
    Q1 Operating Expenses$115.10 mln
    

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for IDEAYA Biosciences Inc is $52.00, about 79.9% above its May 4 closing price of $28.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on IDEAYA Biosciences

    See all news